NCT03582761View on ClinicalTrials.gov

Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71

PHASE4CompletedINTERVENTIONAL
Enrollment

40,000

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
Hand, Foot and Mouth Disease
Interventions
BIOLOGICAL

EV71 vaccine

EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28

Trial Locations (2)

210009

Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing

430079

Hubei Provincial Center for Diseases Control and Prevention, Wuhan

All Listed Sponsors
collaborator

Wuhan Institute of Biological Products Co., Ltd

INDUSTRY

collaborator

Hubei Provincial Center for Disease Control and Prevention

OTHER

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT03582761 - Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71 | Biotech Hunter | Biotech Hunter